Stefan Woxström at AstraZeneca considers the high rates of non-communicable diseases and how governments and healthcare systems can improve their treatments

Pharmafile speaks to Scott Curley about CVD, the impact COVID-19 had on the pharma industry specifically in relation to CVD and the next steps for cardiovascular treatment in the UK

What treatments can be used for diuretic-resistant congestion in chronic heart failure, and what challenges face them?

Patients can benefit from new RNA-based therapeutics for metabolic care

The challenge of cardiovascular disease: Daiichi Sankyo tells Pharmafile about their role in improving access to cardiovascular treatments and the prevention of CVD